Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Authors
Keywords
-
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 290, Issue 8, Pages 4573-4589
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2015-01-01
DOI
10.1074/jbc.m114.595181
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes
- (2014) Matthias Gehringer et al. ChemMedChem
- Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring
- (2014) Kai Zhu et al. Journal of Chemical Information and Modeling
- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
- (2013) Qingsong Liu et al. CHEMISTRY & BIOLOGY
- Targeting kinases: a new approach to treating inflammatory rheumatic diseases
- (2013) David L Simmons CURRENT OPINION IN PHARMACOLOGY
- Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid Arthritis
- (2013) Lesley J. Scott DRUGS
- Lead identification of novel and selective TYK2 inhibitors
- (2013) Jun Liang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis
- (2013) A. L. Rankin et al. JOURNAL OF IMMUNOLOGY
- Design and synthesis of tricyclic cores for kinase inhibition
- (2012) Stacy Van Epps et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors
- (2012) Janusz J. Kulagowski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor
- (2012) Maria A Argiriadi et al. BMC STRUCTURAL BIOLOGY
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
- (2011) Claude Haan et al. CHEMISTRY & BIOLOGY
- Features and development ofCoot
- (2010) P. Emsley et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Targeted covalent drugs of the kinase family
- (2010) Juswinder Singh et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
- (2010) Jill E. Chrencik et al. JOURNAL OF MOLECULAR BIOLOGY
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Covalent Modifiers: An Orthogonal Approach to Drug Design
- (2009) Michele H. Potashman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
- (2009) Neal K. Williams et al. JOURNAL OF MOLECULAR BIOLOGY
- Targeting innate immunity protein kinase signalling in inflammation
- (2009) Matthias Gaestel et al. NATURE REVIEWS DRUG DISCOVERY
- Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase
- (2008) Wooyoung Hur et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now